FAQ Library

FAQ Library published on January 12, 2018
Dr. Lonial briefly summarizes one of the key educational messages delivered at the 2017 American Society of Hematology Annual Meeting.
FAQ Library published on December 13, 2017
Join Dr. Usmani as he discusses when to consider a second autologous stem cell transplant for your multiple myeloma patient.
FAQ Library published on November 8, 2017
In this activity, Dr. Usmani discusses factors to consider when deciding whether to use a patient's previous regimen as salvage treatment.
FAQ Library published on October 11, 2017
Join Dr. Lonial as he gives a concise summary of Bcl-2 directed treatment as a biomarker-driven therapy in myeloma.
FAQ Library published on September 20, 2017
Dr. Orlowski discusses the major side effects associated with the daratumumab, bortezomib and dexamethasone regimen, and how to manage them.
FAQ Library published on September 6, 2017
Join Dr. Orlowski as he explains the major toxicities associated with the daratumumab, lenalidomide, and dexamethasone regimen, and how to manage these adverse events.
FAQ Library published on August 9, 2017
Join Dr. McCarthy as he discusses which patients are likely to have a very fulminant or aggressive relapse, and how to risk-stratify these patients from diagnosis to prognosis.
FAQ Library published on July 26, 2017
Join Dr. Nooka as he explains how to manage patients who are experiencing adverse events with the two approved monoclonal antibodies, elotuzumab and daratumumab.
FAQ Library published on July 19, 2017
Join Dr. Nooka as he explains how to manage a patient who is experiencing adverse events with the only approved HDAC inhibitor, panobinostat.
FAQ Library published on July 12, 2017
Join Dr. Nooka as he explains how to manage patients who are experiencing adverse events with the three approved proteasome inhibitors, carfilzomib, bortezomib, and ixazomib.
Page 3 of 14
Results 21 - 30 of 140